ALTAMIRA THERAPEUTICS LTD (CYTO) Stock Analyst Earnings Estimates
NASDAQ:CYTO - Nasdaq - BMG0360L1349 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 60K | 310K 416.67% | 188.233K -39.28% | -100.00% | 5.835M | ||
| EBITDA YoY % growth | -13.18M -150.57% | -12.68M 3.79% | -1.876M 85.20% | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.26M -151.14% | -12.8M 3.47% | -1.995M 84.41% | -9.106M -356.34% | -11.778M -29.35% | -8.297M 29.56% | |
| Operating Margin | -22,100.00% | -4,129.03% | -1,060.03% | N/A | N/A | -142.19% | |
| EPS YoY % growth | N/A | N/A | N/A | -2.70 | -1.19 55.85% | -1.64 -37.61% |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2023 Q2Q % growth | 62.748K -79.76% | % | ||
| Q2 2023 Q2Q % growth | -100.00% | % | ||
| Q4 2022 Q2Q % growth | 310K 416.67% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 0% | 31.88% |
| Revenue | N/A | N/A | N/A | N/A |